Baidu
map

Eur Heart J:ARB剂量增加对降压效果影响不大

2013-08-28 高晓方 译 cmt

美国一项荟萃分析表明,血管紧张素受体拮抗剂(ARB)剂量增加对降压效果影响不大;氯沙坦的降压效果劣于其他ARB。论文8月21日在线发表于《欧洲心脏杂志》(Eur Heart J)。 研究者对Pubmed、EMBASE和Cochrane数据库进行了检索,并纳入了报告高血压患者应用ARB时24小时动态血压监测的随机临床试验。评估ARB 25%、50%和100%最大剂

血压

美国一项荟萃分析表明,血管紧张素受体拮抗剂(ARB)剂量增加对降压效果影响不大;氯沙坦的降压效果劣于其他ARB。论文8月21日在线发表于《欧洲心脏杂志》(Eur Heart J)。【原文下载

研究者对Pubmed、EMBASE和Cochrane数据库进行了检索,并纳入了报告高血压患者应用ARB时24小时动态血压监测的随机临床试验。评估ARB 25%、50%和100%最大剂量时动态血压降低情况。对比氯沙坦50和100 mg与其他ARB 50%和100%最大剂量的24小时降压效果。


结果显示,共有包括15,289例患者的62项研究符合纳入标准;受试者平均年龄56岁,男性60%,中位持续时间10周。总体而言,ARB剂量反应曲线较为平坦,25%、50%和100%最大剂量时收缩/舒张压分别降低10.3/6.7、11.7/7.6和13.0/8.3 mmHg。氯沙坦50 mg的动态血压降低效果劣于50%最大剂量ARB(P=0.0002),100 mg的降压效果(3.9/2.2 mm Hg)亦劣于100%最大剂量ARB。

原始出处:

Makani H, Bangalore S, Supariwala A, Romero J, Argulian E, Messerli FH.Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis.Eur Heart J. 2013 Aug 21. 【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997536, encodeId=9635199e53675, content=<a href='/topic/show?id=81cf9814368' target=_blank style='color:#2F92EE;'>#降压效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98143, encryptionId=81cf9814368, topicName=降压效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Mon Apr 28 10:03:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291799, encodeId=b4851291e99c6, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Aug 30 09:03:00 CST 2013, time=2013-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355789, encodeId=a7801355e896d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 30 09:03:00 CST 2013, time=2013-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562186, encodeId=5814156218634, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 30 09:03:00 CST 2013, time=2013-08-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1997536, encodeId=9635199e53675, content=<a href='/topic/show?id=81cf9814368' target=_blank style='color:#2F92EE;'>#降压效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98143, encryptionId=81cf9814368, topicName=降压效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Mon Apr 28 10:03:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291799, encodeId=b4851291e99c6, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Aug 30 09:03:00 CST 2013, time=2013-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355789, encodeId=a7801355e896d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 30 09:03:00 CST 2013, time=2013-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562186, encodeId=5814156218634, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 30 09:03:00 CST 2013, time=2013-08-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1997536, encodeId=9635199e53675, content=<a href='/topic/show?id=81cf9814368' target=_blank style='color:#2F92EE;'>#降压效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98143, encryptionId=81cf9814368, topicName=降压效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Mon Apr 28 10:03:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291799, encodeId=b4851291e99c6, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Aug 30 09:03:00 CST 2013, time=2013-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355789, encodeId=a7801355e896d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 30 09:03:00 CST 2013, time=2013-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562186, encodeId=5814156218634, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 30 09:03:00 CST 2013, time=2013-08-30, status=1, ipAttribution=)]
    2013-08-30 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1997536, encodeId=9635199e53675, content=<a href='/topic/show?id=81cf9814368' target=_blank style='color:#2F92EE;'>#降压效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98143, encryptionId=81cf9814368, topicName=降压效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Mon Apr 28 10:03:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291799, encodeId=b4851291e99c6, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Aug 30 09:03:00 CST 2013, time=2013-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355789, encodeId=a7801355e896d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 30 09:03:00 CST 2013, time=2013-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562186, encodeId=5814156218634, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 30 09:03:00 CST 2013, time=2013-08-30, status=1, ipAttribution=)]
    2013-08-30 slcumt

相关资讯

Arch Neurol:ARB类降压药对老年性痴呆(AD)患者有益

患者入选流程图 最近一项尸检研究表明,使用血管紧张素受体拮抗剂(ARB)类的降压药与脑内阿尔茨海默病样病理出现少相关。研究者发现采用CERAD制定的神经病理学标准,生前服用ARB类降压药的AD患者与服用其它降压药的患者相比(37% vs. 54%,P=0.005),病理表现较轻。在校正年龄、性别、APOE分型和血压等变量后,生前服用ARB类降压药的AD患者与服用其它降压的患者尸检AD病理变化的O

Baidu
map
Baidu
map
Baidu
map